News tagged with pioglitazone
Pioglitazone
Pioglitazone is a prescription drug of the class thiazolidinedione (TZD) with hypoglycemic (antihyperglycemic, antidiabetic) action. Pioglitazone is marketed as trademarks Actos in the USA, Canada, the UK and Germany, Glustin in Europe,"Glizone" and "Pioz" in India by Zydus CND and USV respectively and Zactos in Mexico by Takeda Pharmaceuticals. Actos was the tenth-best selling drug in the U.S. in 2008, with sales exceeding $2.4 billion. Its cardiovascular safety profile compares favorably with rosiglitazone (Avandia), which was withdrawn after concerns about an increased risk of cardiac events, but pioglitazone has subsequently been found to be associated with bladder tumors and has been withdrawn in some countries.
For more information about Pioglitazone, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Pilot study demonstrates safety of diabetes medication for patients with Alzheimer's disease
A pilot study suggests the diabetes medication pioglitazone is generally well tolerated and may warrant further study as a treatment for patients with Alzheimer's disease, according to a report posted online today that will ...
Medicine & Health / Neuroscience
Sep 13, 2010 |
not rated yet |
0
Diabetes drug linked to increased risk of heart failure
Rosiglitazone, a drug used to treat type 2 diabetes, is associated with an increased risk of heart failure and death among older patients compared to a similar drug (pioglitazone), concludes a study published on BMJ.com today.
Medicine & Health / Medications
Aug 20, 2009 |
5 / 5 (2) |
0